US · Healthcare · Biotechnology
EPS came in at -0.76 against a street estimate of -0.66 — a miss of 15.2%.
Analysts rate Jade Biosciences, Inc. a strong buy (10 buy, 0 hold, 0 sell out of 10) with an average price target of $50.12.
| Fund | Stake |
|---|---|
| FMR Inc | 14.35% |
| Jupiter Topco LLC | 9.86% |
| Fairmount Funds Management LLC | 7.16% |
| RA Capital Management, LLC | 5.77% |
| VR Adviser, LLC | 5.06% |
| HHG PLC | 4.88% |
| Bellevue Group AG | 4.81% |
| Paradigm Biocapital Advisors LP | 4.49% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 HEADLINE NUMBERS • Jade announced preclinical data for JADE301, an anti-interferon beta (IFN-β) monoclonal antibody being developed for dermatomyosit | 2026-09-30 |
| Quarterly report · Q2 2026 JADE BIOSCIENCES, INC. – 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash and Investments Combined: $461.2 million as of June 30, 2026 (cash $107.3M + | 2026-08-10 |
| Results announced · Q3 2026 JADE BIOSCIENCES Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash, cash equivalents, and investments: $461.2 million as of June 30, 2026 (u | 2026-08-10 |
| Material agreement · Q2 2026 JADE BIOSCIENCES, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company entered into License Agreement with Paragon Therapeutics on June 29, 2026 • Up to $2 | 2026-07-01 |
| Board / officer change · Q2 2026 JADE BIOSCIENCES, INC. (JBIO) – 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Board Appointment: Jade Biosciences appointed Mark Eisner, M.D., M.P.H. | 2026-06-26 |
| Charter / bylaws change · Q2 2026 JADE BIOSCIENCES, INC. – 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Company is an emerging growth company incorporated in Nevada, trading on Nasdaq | 2026-06-11 |
| Quarterly report · Q1 2026 JADE BIOSCIENCES, INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $55.1 million as of March 31, 2026 (down from $88.4 million at Decem | 2026-05-07 |
| Proxy statement · Q2 2026 JADE BIOSCIENCES, INC. – 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect Christopher Cain, Ph.D. and Tom Frohlich a | 2026-04-28 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Jade Biosciences, Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.